Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;28(3):907-911.
doi: 10.1007/s10461-023-04197-8. Epub 2023 Oct 4.

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy

Angelo Roberto Raccagni  1 , Laura Galli  2 , Maria Francesca Lucente  3 , Caterina Candela  3 , Riccardo Lolatto  2 , Benedetta Trentacapilli  3 , Giacomo Ponta  3 , Emanuela Messina  2 , Nicola Gianotti  2 , Antonella Castagna  3   2 , Silvia Nozza  3   2
Affiliations

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy

Angelo Roberto Raccagni et al. AIDS Behav. 2024 Mar.

Abstract

Aim was to investigate the propensity to switch to long-acting injectable HIV pre-exposure prophylaxis (PrEP) with cabotegravir among oral PrEP-experienced men who have sex with men. Out of 377 PrEP users, 325 (86.2%) were interested (would like = 210) or considering (would consider = 115) switch to long-acting PrEP. At multivariable analysis, the odds ratio of interest in long-acting PrEP in non-adherent vs. adherent individuals to oral PrEP was 5.03 (95%CI = 1.73-14.61,p = 0.003) and of consideration 1.63 (95%CI = 0.51-5.23,p = 0.410). We observed very high propensity to switch to long-acting PrEP, particularly among non-adherent users. Rapid availability of long-acting PrEP might address unmet needs of PrEP users in Italy.

Keywords: Cabotegravir; Long acting; PrEP; Pre-exposure prophylaxis.

PubMed Disclaimer

References

    1. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595–608. https://doi.org/10.1056/NEJMoa2101016 . - DOI - PubMed - PMC
    1. Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9(8):e554–62. https://doi.org/10.1016/S2352-3018(22)00133-3 . - DOI - PubMed
    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60. https://doi.org/10.1016/S0140-6736(15)00056-2 . - DOI - PubMed - PMC
    1. Ambrosioni J, Petit E, Liegeon G, Laguno M, Miró JM. Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV. 2021;8(3):e166–74. https://doi.org/10.1016/S2352-3018(20)30271-X . - DOI - PubMed
    1. Girometti N, McCormack S, Tittle V, McOwan A, Whitlock G, 56 Dean Street Collaborative Group. Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes. AIDS. 2022;36(4):561–6. https://doi.org/10.1097/QAD.0000000000003143 . - DOI - PubMed

LinkOut - more resources